Pediatric Neuro-Oncology Research Lab striving to improve therapies for children with brain tumors through basic, transitional and clinical research.
University of Michigan
Joined July 2020
- Tweets260
- Following290
- Followers763
- Likes371
Koschmann Lab retweeted
As part of the American Association for Cancer Research @AACR Report for 2025, Dr. @CarlKoschmann is featured in a new video highlighting Kaley Ihlenfeldt's journey with ONC201, the first FDA-approved therapy for recurrent DMG.
Learn more: michmed.org/28ykk.
Koschmann Lab retweeted
Another incredible @chadtough Run Tough 5K today. Amazing showing by @umichmedicine labs @vennetilab @KoschmannLab @johnprensner, Children’s CTSU, and @MottChildren employees and families - all for the most important cause- defeating DIPG.
Koschmann Lab retweeted
So honored to receive this support from #UCanCerVive on behalf of @KoschmannLab! Will get right to work on our shared commitment to improve treatments for children with brain tumors.
Koschmann Lab retweeted
We're excited to share this roadmap that was put together by researchers who attended our 2023 Research Workshop!
Announcing the release of the Roadmap for the Treatment of Pediatric DMG today in @Cancer_Cell which was led by @vennetilab and @KoschmannLab and put together by the brilliant team of researchers who came together for the @chadtough Defeat DIPG Workshop: sciencedirect.com/science/ar…
Koschmann Lab retweeted
Announcing the release of the Roadmap for the Treatment of Pediatric DMG today in @Cancer_Cell which was led by @vennetilab and @KoschmannLab and put together by the brilliant team of researchers who came together for the @chadtough Defeat DIPG Workshop: sciencedirect.com/science/ar…
Koschmann Lab retweeted
So happy to share our consensus paper on understanding and treating #DIPG from the @chadtough foundation workshop held this year in #AnnArbor. Thank you to our amazing scientists, collaborators, and families who made this possible!!!
cell.com/cancer-cell/fulltex…
Koschmann Lab retweeted
Wow! We are so thankful for YOU! We’re thrilled to report that, in partnership with 50 families, we raised over $675,000 for @chadtough for this year’s Giving Tuesday. Thank you from the bottom of our hearts. 💛
Together, we will #DefeatDIPG.
💛 The Mosiers
Koschmann Lab retweeted
November issue—
Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al.
bit.ly/3T1mCSU
@umichmedicine @UMRogelCancer @MottChildren #DIPG
Koschmann Lab retweeted
Very excited to report the publication in @NeuroOnc of a project led by Richard Lu at #cchmc along with Richard Graham and @KoschmannLab. academic.oup.com/neuro-oncol…
Koschmann Lab retweeted
November issue—
Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al.
bit.ly/3QZMhKv
@umichmedicine @UMRogelCancer @MottChildren #DIPG
Koschmann Lab retweeted
November issue—
Clinical efficacy of ONC201 in H3K27M-#DMG, by @vennetilab, @AbedKawakibi, Sunjong Ji, @sebastianw, Stefan Sweha, Mateus Mota, Matthew Pun, Sharon Gardner, @OdiaYazmin, @KoschmannLab et al.
bit.ly/3QZMhKv
@umichmedicine @UMRogelCancer @MottChildren #DIPG
Koschmann Lab retweeted
We love our Dr. Carl! Thank you for working so hard to #DefeatDIPG! Always proud to support your work! @CarlKoschmann #SNO2023
Our fearless leader @CarlKoschmann presenting now on clinical efficacy of ONC201 treatment of H3K27M altered DMGs and the complex integrated epigenetic and mitochondrial pathways ONC201 impacts #SNO2023
Koschmann Lab retweeted
Excellent Presentation by @jackwadden from @KoschmannLab at SNO2023 (@NeuroOnc) on Nanopore sequencing plasma for H3K27M!
Koschmann Lab retweeted
250+ clinical trials failed to improve outcomes for #DMG, #DIPG. Clinical trials of a new compound ONC201 reported by @KoschmannLab & @vennetilab represents a potential "crack in the armor:" michmed.org/8N5me
Koschmann Lab retweeted
New study in @CD_AACR reports on 2 clinical trials testing ONC201 in pts with H3K27M-mutated diffuse midline gliomas. Median OS was ~22 months for tumors that had not recurred and 1/3 of patients lived >2 years: michmed.org/8N5me @KoschmannLab @vennetilab
Koschmann Lab retweeted
Clinical trials led by @UMRogelCancer show longer survival in patients with diffuse midline glioma treated with ONC201; study also explains underlying mechanism of the drug’s success: michmed.org/8N5me @KoschmannLab, @vennetilab #DIPG #DMG
Koschmann Lab retweeted
Delays in diagnosis lead to delays in treatment – time kids with #braintumors don’t have. We've teamed up with longtime funding partner Catching Up With Jack to make faster cancer diagnosis and monitoring a reality: curethekids.org/news/pediatr… #childhoodcancer
Koschmann Lab retweeted
Researchers from @MottChildren and @UMRogelCancer Center have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. myumi.ch/VMEnq
Koschmann Lab retweeted
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with pediatric brain tumors #DMG #DIPG: michmed.org/8N5me
Read the paper: aacrjournals.org/cancerdisco…
@KoschmannLab @vennetilab @CD_AACR
Koschmann Lab retweeted
ONC201 is an experimental drug that selectively kills cancer cells.
newsweek.com/scientists-find…